彭布罗利珠单抗
医学
危险系数
内科学
化疗
肿瘤科
置信区间
癌症
队列
胃肠病学
外科
免疫疗法
作者
Kei Muro,Kohei Shitara,Kensei Yamaguchi,Takaki Yoshikawa,Hironaga Satake,Hiroki Hara,Naotoshi Sugimoto,Nozomu Machida,Masahiro Goto,Hisato Kawakami,Kenji Amagai,Yasushi Omuro,Taito Esaki,Shuichi Hironaka,Tomohiro Nishina,Yoshito Komatsu,Hisahiro Matsubara,Shinichi Shiratori,Shirong Han,Taroh Satoh
标识
DOI：10.1007/s12029-023-00920-9
摘要
Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-062 (first line). We characterized efficacy and safety of pembrolizumab monotherapy in Japanese patients across several lines of therapy in these studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
皖公网安备34019202002308
